Logo image of ALLR

ALLARITY THERAPEUTICS INC (ALLR) Stock Fundamental Analysis

NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD

0.8813  +0.04 (+4.16%)

Premarket: 0.88 0 (-0.15%)

Fundamental Rating

2

Taking everything into account, ALLR scores 2 out of 10 in our fundamental rating. ALLR was compared to 559 industry peers in the Biotechnology industry. ALLR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALLR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALLR had negative earnings in the past year.
ALLR had a negative operating cash flow in the past year.
In the past 5 years ALLR always reported negative net income.
In the past 5 years ALLR always reported negative operating cash flow.
ALLR Yearly Net Income VS EBIT VS OCF VS FCFALLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -117.80%, ALLR is not doing good in the industry: 80.68% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -185.17%, ALLR is doing worse than 66.55% of the companies in the same industry.
Industry RankSector Rank
ROA -117.8%
ROE -185.17%
ROIC N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALLR Yearly ROA, ROE, ROICALLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

ALLR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLR Yearly Profit, Operating, Gross MarginsALLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ALLR has been increased compared to 1 year ago.
Compared to 5 years ago, ALLR has more shares outstanding
Compared to 1 year ago, ALLR has an improved debt to assets ratio.
ALLR Yearly Shares OutstandingALLR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M
ALLR Yearly Total Debt VS Total AssetsALLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -8.47, we must say that ALLR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.47, ALLR is not doing good in the industry: 70.48% of the companies in the same industry are doing better.
ALLR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.47
ROIC/WACCN/A
WACCN/A
ALLR Yearly LT Debt VS Equity VS FCFALLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ALLR has a Current Ratio of 2.75. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.75, ALLR is not doing good in the industry: 67.26% of the companies in the same industry are doing better.
ALLR has a Quick Ratio of 2.75. This indicates that ALLR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALLR (2.75) is worse than 65.65% of its industry peers.
Industry RankSector Rank
Current Ratio 2.75
Quick Ratio 2.75
ALLR Yearly Current Assets VS Current LiabilitesALLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

ALLR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.83%, which is quite impressive.
EPS 1Y (TTM)97.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALLR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.92% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALLR Yearly Revenue VS EstimatesALLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2M 4M 6M 8M
ALLR Yearly EPS VS EstimatesALLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -500K -1M -1.5M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLR. In the last year negative earnings were reported.
Also next year ALLR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLR Price Earnings VS Forward Price EarningsALLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLR Per share dataALLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20K -40K -60K -80K -100K

4.3 Compensation for Growth

ALLR's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.41%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

ALLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALLARITY THERAPEUTICS INC

NASDAQ:ALLR (6/9/2025, 8:08:50 PM)

Premarket: 0.88 0 (-0.15%)

0.8813

+0.04 (+4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners2.36%
Inst Owner Change-11.61%
Ins Owners16.8%
Ins Owner Change71.58%
Market Cap13.29M
Analysts43.33
Price TargetN/A
Short Float %8.2%
Short Ratio1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-123690
EYN/A
EPS(NY)-47.86
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.8%
ROE -185.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.51%
ROA(5y)-87.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.75
Quick Ratio 2.75
Altman-Z -8.47
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.89%
EPS Next Y99.94%
EPS Next 2Y41.41%
EPS Next 3Y25.98%
EPS Next 5Y18.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.21%
OCF growth 3YN/A
OCF growth 5YN/A